Klaus Dornmair

Title: Klaus Dornmair: Innovator in Major Histocompatibility Complex Molecules

Introduction

Klaus Dornmair is a notable inventor based in Palo Alto, California. He has made significant contributions to the field of immunology, particularly in the development of major histocompatibility complex (MHC) molecules. His work has implications for therapeutic applications, drug screening, and diagnostics.

Latest Patents

Klaus Dornmair holds 1 patent related to MHC molecules. His patent describes processes for increasing the antigen binding capacity of MHC molecules. These processes involve treating an antigen-bound MHC molecule with an unfolding agent to release undesired antigens, followed by treatment with a refolding agent to produce a functional MHC molecule. Additionally, his invention includes compositions of MHC molecules that are free of undesired antigens or bound with specific desired antigens, which can be used in combination with pharmaceutically acceptable carriers and cytotoxic agents.

Career Highlights

Klaus Dornmair is affiliated with Leland Stanford Junior University, where he continues to advance research in immunology. His innovative approaches have garnered attention in the scientific community, contributing to the understanding of antigen presentation and immune response.

Collaborations

Klaus Dornmair has collaborated with Harden M McConnell, further enhancing the research and development of MHC-related technologies.

Conclusion

Klaus Dornmair's work in the field of major histocompatibility complex molecules represents a significant advancement in immunological research. His innovative processes and compositions have the potential to impact therapeutic strategies and diagnostics in meaningful ways.